Signals Inbox·August 23, 2026·Consumer Health

What's up with Lady Gaga's new startup?

Lady Gaga’s Outer Biosciences is not another celebrity skincare line: it is an early biotech platform using living donated human skin, automation and machine learning to discover ingredients and sell research, with enough real science to be interesting but not yet enough commercial proof to call it a breakthrough.

Q1Is Lady Gaga actually launching another skincare brand?

No: Lady Gaga is backing a biotech company that discovers and tests skin-active molecules for other companies.

Outer Biosciences has existed since 2022 but only recently stepped into public view. The company currently has 19 employees, has raised roughly $23 million and is run by Gaga’s partner Michael Polansky. Gaga, whose legal name is Stefani Germanotta, sits on the board.

There is no Outer moisturizer or serum to buy. The company plans to develop ingredients that beauty companies can formulate into their own products, while also selling research work to beauty, biotech and pharmaceutical customers.

That puts Outer several layers upstream from Haus Labs. Gaga already owns the consumer brand. With Outer, she is involved in the science that could eventually create some of the ingredients brands compete over.

Q2What does Outer Biosciences actually do?

Outer Biosciences currently combines living human skin, automated lab experiments and machine learning to search for new skincare ingredients and study how skin responds to treatments.

Its YUNA platform starts with full-thickness human skin containing the epidermis, dermis and several of the cell populations found in normal skin. Outer can keep that tissue usable for several weeks while researchers expose it to compounds, inflammation, UV damage or other interventions.

The company then measures what changes inside the tissue. Its current system collects transcriptomic, biochemical, histological and other biological measurements, giving researchers a much richer answer than “this compound killed the cells” or “this one did something interesting.”

Machine-learning models help decide which compounds deserve physical testing. Promising candidates move through automated cell assays and eventually into donated human skin. The experimental results then go back into the models.

The loop is straightforward: make predictions, test them on real human tissue, learn from the results and repeat.

Q3Where does Outer get the human skin?

Outer gets its skin from consented human tissue donations, mostly surgical tissue that would otherwise be discarded.

According to the company, its network includes hospitals, medical research centers, biobanks and tissue-procurement organizations across North America. Outer says it only receives de-identified adult tissue designated for research and does not take tissue that could have been used for transplantation.

In a recent TechCrunch interview, Polansky named the National Disease Research Interchange and the Cooperative Human Tissue Network among the organizations involved in sourcing. Much of the tissue comes from elective procedures such as plastic surgery.

This also gives Outer access to something a standardized lab-grown model struggles to reproduce: biological variation between actual people. Its research can involve different ages, skin types, racial backgrounds, genders and body areas.

That diversity could become particularly useful for problems such as pigmentation, inflammation and aging, where two people can respond very differently to the same intervention.

Q4Why is Lady Gaga involved in a biotech company?

Gaga’s involvement makes much more sense once we connect Outer to what she has already been building in beauty.

Polansky says the original idea for Outer came from Gaga. She now sits on its board, while he runs the company day to day with a team that includes scientists and engineers with experience in organ-on-chip technology and biotech.

There is also a direct bridge to Haus Labs. Outer chief scientist Kyung-Jin Jang sits on Haus Labs’ scientific advisory board, and Polansky says the two companies have already worked on projects together.

Haus Labs has spent years pushing “skincare-infused makeup” and building product stories around ingredients such as fermented arnica. Outer takes that interest further upstream. Instead of choosing among ingredients developed elsewhere, it can potentially create new ones.

Keeping the companies separate also leaves Outer free to work with other beauty brands, ingredient suppliers and pharmaceutical companies. That makes the opportunity much larger than using the technology only inside Gaga’s own makeup business.

Gaga’s fame will obviously help with attention and industry access. More interesting: Outer spent years developing quietly before leaning into that advantage. For a celebrity-linked biotech company, science first and publicity later is a healthier order.

Q5Is keeping human skin alive for four weeks actually a big deal?

Yes: extending native donated human skin from roughly a week to around four weeks is a meaningful experimental jump.

Genoskin, one of the established companies in this field, currently keeps its NativeSkin model viable and functional for up to ten days and generally recommends experiments within about a week because variability increases later. Outer reports more than 30 days, and its bioRxiv research shows tissue maintained for up to four weeks.

That difference opens experiments that unfold too slowly for a short window. Collagen remodeling, persistent inflammation, senescence, wound repair and repeated environmental damage can develop over weeks.

The distinction between native and reconstructed skin is also important. Researchers can grow engineered skin models for long periods, and companies such as LabSkin already offer sophisticated full-thickness reconstructed tissue. Outer works with tissue that came directly from a human donor, retaining the donor’s original architecture and biological variation.

If its published results hold up, Outer has stretched one of the important constraints of native ex vivo skin research by roughly three to four times.

How Outer compares with other human-skin testing approaches

Q6Where does the AI actually help Outer Biosciences?

AI helps Outer narrow an enormous chemical search space before the company spends time and money testing compounds physically.

Outer says its current models can computationally pre-screen roughly 750 million compounds a year. Candidates are ranked for things such as biological activity, toxicity, manufacturability and intellectual-property potential, then filtered through automated laboratory assays.

The more useful number is the discovery rate.

Polansky told TechCrunch that Outer initially used a more brute-force process based partly on scientific literature and work involving the National Cancer Institute. That produced “a couple” of leads over around 18 months. Today, he says, the company is generating roughly one new candidate every six weeks.

If we interpret “a couple” literally as two, the claimed candidate-generation rate has increased by roughly six times.

That is a better way to judge the AI than counting how many molecules a model can scan. Outer needs predictions that survive progressively harder experiments. Screening hundreds of millions of compounds means very little if the winners fail once they touch real tissue.

Q7Does Outer Biosciences have real scientific evidence?

The science is credible enough to take seriously today, with one big caveat: outsiders have yet to independently replicate the platform.

Outer published a bioRxiv preprint in 2026 showing that its system preserved native tissue architecture and several epidermal, stromal and immune-associated molecular programs during long experiments.

The researchers did more than show that the tissue still looked intact. They induced persistent inflammatory signaling and then used the JAK inhibitor tofacitinib, which broadly suppressed the expected inflammatory programs. They exposed tissue to UVB and found that sunscreen partially reduced the resulting biological damage. They also ran experiments involving older donor tissue and aging-related pathways.

Those are sensible responses to known interventions, which makes the platform more convincing.

Outer has also presented work at the Society for Investigative Dermatology, the Society of Toxicology, World ADC London and the New York Society of Cosmetic Chemists.

The caveat deserves real weight. The main paper is still a preprint, and every listed author is an Outer employee or equity holder. We would become considerably more confident once independent laboratories reproduce the results or peer-reviewed studies appear from external groups.

Q8Has Outer actually discovered a useful skincare ingredient yet?

Outer has a real pipeline today, although none of its ingredients has reached the commercial finish line yet.

Polansky says six ingredient leads are currently active, with several dozen earlier-stage hits behind them. He also says four of the six appear capable of reaching commercialization.

Four out of six would be an unusually strong 67% progression rate if it actually happens. Right now, however, that 67% is management’s expectation rather than an observed success rate.

A candidate still has to survive safety work, manufacturing scale-up, formulation, stability testing, regulatory requirements and ultimately testing on actual people. Outer itself says building a dedicated product-development team is one of the next steps because scientists currently handle much of that work manually.

The next year or two will be much more informative than another increase in screening capacity. The first ingredient that makes it into a real product will tell us far more about Outer than another million computational predictions.

Q9Could Outer’s human-skin dataset become its real moat?

Yes, and the proprietary experimental data may ultimately be harder to copy than the machine-learning models.

Wing Venture Capital says YUNA has already generated more than 10 terabytes of proprietary data across more than 300 donors and 10,000 treatments. Outer says individual compounds can produce more than 30,000 multimodal datapoints across transcriptomic, biochemical and histological measurements.

The hard-to-copy part is how those data are produced.

Outer knows which compound was applied, at what dose, to which donor tissue and what happened afterward. Failed predictions are useful too because they teach the model where its previous assumptions were wrong.

A competitor can read the same scientific papers and train on many of the same public chemical databases. Reproducing years of standardized experiments on hundreds of human donors is much harder.

We should still keep the scale in perspective. Three hundred donors is substantial for a young experimental platform and tiny compared with the diversity of human skin worldwide. The moat gets stronger only if the company keeps adding high-quality experiments and proves that the resulting models become measurably better at predicting what works.

Q10Why do we even need new skincare ingredients?

Because the number of skincare products is huge while the pool of genuinely differentiated, well-supported active ingredients is much smaller.

Walk through the anti-aging category and the same families appear again and again: retinoids, niacinamide, vitamin C, exfoliating acids, peptides, hyaluronic acid and antioxidants. Brands can change formulation, concentration, delivery method and marketing while relying on familiar biological mechanisms underneath.

Polansky argues that the universe of skincare actives backed by meaningful research is surprisingly small. The exact number is impossible to pin down because “active ingredient” has a strict regulatory meaning for some products and a much looser cosmetic meaning elsewhere.

Still, thousands of new beauty SKUs do not translate into thousands of new biological mechanisms.

A genuinely novel compound with convincing efficacy can therefore become valuable across many products and potentially many brands. It can also generate patents, licensing income and stronger product claims.

Outer is betting that discovering new actives is a better place to create value than launching yet another variation of an existing serum.

Q11Is there a real market for testing products on living human skin?

Yes: companies are already paying for human-skin testing, so Outer does not have to invent the market.

Genoskin says it has served more than 500 customers worldwide, and its current website says 75% of the largest pharmaceutical companies have run studies using its platforms. Its models are used for efficacy, irritation, absorption, inflammatory responses, injectables, medical devices and other applications.

The beauty industry also has a structural reason to use alternatives to animal testing. Europe has prohibited animal testing for cosmetic purposes for years, while drug developers increasingly use human-relevant models to catch problems that simpler cell systems or animal studies may miss.

Outer currently competes for part of that existing research spend with a longer-duration native tissue platform and a larger data layer around each experiment.

Its commercial hurdle is therefore fairly concrete: can the extra weeks and deeper measurements give customers answers good enough to justify choosing Outer over established alternatives?

If yes, research services alone could become a meaningful business even before one of Outer’s own ingredients becomes a hit.

Q12Could pharma eventually become bigger for Outer than skincare?

Possibly, and pharma may eventually become Outer’s more valuable market even if beauty gives it the faster route to revenue.

The same platform used to test an anti-aging ingredient can also study inflammation, wound healing, drug toxicity and treatment responses in human tissue.

Outer is already doing this. In his recent interview, Polansky said a pharmaceutical partner is using the platform to investigate why certain cancer drugs cause severe skin rashes. The company has also presented research on skin toxicity from antibody-drug conjugates, a rapidly growing class of cancer medicines.

Those problems can carry much higher economic stakes than choosing the next moisturizer ingredient. A severe dermatological side effect can limit dosing, hurt patient adherence or derail a drug program worth hundreds of millions of dollars.

Beauty still offers a useful starting point because commercial development is faster and cheaper than creating a new pharmaceutical drug. Pharma adds a second path where the same tissue technology can answer more expensive questions.

That combination is one reason Outer looks broader than a skincare startup today. Its underlying product is access to unusually rich experiments on human skin.

Q13How does Outer Biosciences make money today?

Outer is already generating revenue through collaborative research, while ingredients and licensing could create larger revenue streams later.

Polansky says current partners include pharmaceutical companies and consumer beauty brands. A company can bring Outer a compound, a formulation or a biological question and pay for experiments using the platform.

Outer also wants to commercialize molecules it discovers itself. Those could be sold as finished ingredients, licensed to brands or co-developed with ingredient manufacturers that already know how to produce and distribute them at scale.

The company has deliberately kept those options open. Polansky says he has yet to decide whether Outer eventually becomes primarily an ingredient business, a licensing company or a company built around one particularly valuable molecule.

That flexibility is useful at this stage because the best economics are still unknown. A research contract generates money sooner. A successful proprietary ingredient could generate much more money. A pharmaceutical discovery could change the company again.

For now, research revenue buys Outer time to find out which path is strongest.

Q14What could make Outer Biosciences fail?

The biggest risk is brutally simple: promising results in donated skin can still disappoint once a product reaches living people.

Human skin sitting in a lab is biologically rich, but it lacks the full circulation, metabolism, hormonal system and continuous immune activity of an actual person. Better laboratory models can reduce uncertainty without eliminating it.

The second problem comes after discovery. Outer needs compounds that can be manufactured cheaply enough, remain stable, survive formulation, clear safety requirements and produce an effect consumers can actually notice. Scientific novelty alone will not make an ingredient commercially useful.

Competition is another constraint. Genoskin already has hundreds of customers and more than 100 peer-reviewed publications around its broader platform. Reconstructed skin companies offer other advantages. Large beauty and pharmaceutical companies also have internal research capabilities.

Outer therefore has to prove more than technical novelty. Its system has to produce better decisions or better compounds often enough that customers keep paying for it.

And its current ingredient pipeline is still small. A few failed leads could quickly change how impressive the early conversion numbers look.

Q15What would prove that Outer Biosciences really works?

One commercially successful ingredient would change the conversation, while repeated successes would prove that Outer has built a discovery engine.

We would put much more weight on the following milestones than on another announcement about screening capacity.

The first is independent scientific replication of YUNA. The second is an Outer-discovered molecule entering a real commercial product. The third is controlled human data showing a meaningful effect. Then we want to see the process work again with a different molecule.

That last step is the hardest and the most valuable. One hit can happen for many reasons. Two or three unrelated ingredients discovered through the same process would start to show that the platform itself deserves the credit.

The same standard should apply to pharma. A paying research partnership is encouraging. Evidence that an Outer experiment correctly predicted a clinically important human response would be much stronger.

Milestones that would prove Outer Biosciences really works

Q16So, what’s actually up with Lady Gaga’s new skincare startup?

Outer Biosciences currently looks like a serious early biotech bet with unusually powerful celebrity distribution, while the breakthrough case remains unproven.

The interesting part of the company is surprisingly far removed from celebrity skincare. Gaga and Polansky have helped build a system that lets researchers experiment on donated human skin for much longer than the usual native-tissue window, collect unusually deep biological data and use those experiments to improve predictions about which molecules deserve further testing.

There is enough substance here to take Outer seriously. The tissue platform has produced publishable experimental results. Research customers are already paying the company. The AI-assisted discovery process appears to be producing candidates far faster than Outer’s earlier approach. Six ingredients are now moving through its pipeline.

The evidence becomes thinner once we reach the outcome that ultimately matters: an Outer discovery that works convincingly on real people and becomes a successful commercial product.

That is why the company is interesting right now. We are looking at a plausible new piece of R&D infrastructure for the skin industry at exactly the point where it is leaving the laboratory and starting to face commercial reality.

If the first few ingredients survive that transition, Gaga will have built something much more unusual than another celebrity beauty brand: a company sitting upstream of the brands, discovering some of the molecules they may eventually sell.

For now, Outer has earned our attention. It has yet to earn the word “breakthrough.”